Health care stocks retreated late Friday afternoon, with the NYSE Health Care Index down 0.2% and the Health Care Select Sector SPDR Fund (XLV) shedding 0.3%.
The iShares Biotechnology ETF (IBB) was down 0.1%.
In corporate news, Vivos Therapeutics (VVOS) shares jumped 9% after the company said it issued a $1.1 million convertible promissory note to V-Co Investors 2, with proceeds to be used for the acquisition of The Sleep Center of Nevada.
Bicara Therapeutics (BCAX) shares fell 43% after the company said late Thursday that its latest trial for a potential head and neck cancer treatment has yet to reach median overall survival.
Merus (MRUS) shares surged 32% after the company reported favorable interim cancer trial results in the previous day.
Imunon (IMNN) shares rallied 175%. It reported positive data showing an improvement in overall and progression-free survival from a phase 2 trial of IMNN-001 in ovarian cancer.
Fulcrum Therapeutics (FULC) shares gained 5% after Leerink upgraded the stock to outperform from market perform and raised its price target to $12 from $4.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。